BoB@JPM: Ron Cooper, enGene

BoB@JPM: Ron Cooper, enGene

Author: Ben Comer January 26, 2026 Duration: 55:57

We love to hear from our listeners. Send us a message.

On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he’s now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders. Cooper talks about the importance of keeping development, financing, and hiring in sync as biotech companies grow, his experiences surviving near-death cash deficits, the importance of investing early in CMC, and what to expect in 2026.  

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/



Navigating the complex journey from a promising scientific idea to a commercially viable therapy involves far more than lab work. Business Of Biotech, hosted by Ben Comer, exists in that crucial space where scientific ambition meets real-world execution. This podcast speaks directly to the founders, executives, and visionaries steering emerging biopharma companies, offering a grounded conversation about the non-scientific hurdles that define success. You'll hear detailed discussions on the organizational, financial, and operational realities of the industry-from securing funding and building a team to managing clinical trials, manufacturing, and regulatory pathways. Each episode leans on the hard-earned wisdom of accomplished guests who share commentary and practical best practices. The focus is consistently on the multifaceted challenges leaders face while trying to bring a company from its earliest stages to impact in the clinic and the market. For anyone involved in building a life sciences company, this podcast provides an essential, candid look at the entire ecosystem, making the daunting path of biotech entrepreneurship feel a bit more navigable and a lot less lonely.
Author: Language: English Episodes: 100

Business Of Biotech
Podcast Episodes
BoB@JPM: Nima Farzan, Latigo Biotherapeutics [not-audio_url] [/not-audio_url]

Duration: 43:32
We love to hear from our listeners. Send us a message. In this final installment of our episodes recorded and filmed on-site at the JP Morgan Healthcare Conference, Nima Farzan, CEO of Latigo Biotherapeutics, shares his…
BoB@JPM: Kasper Roet, Ph.D., QurAlis [not-audio_url] [/not-audio_url]

Duration: 43:46
We love to hear from our listeners. Send us a message. Dr. Kasper Roet's hands-on work at the Dutch Brain Bank informed his leadership at the biotech QurAlis, where three clinical programs targeting specific genetic mech…
BoB@JPM: Rick Modi, Affinia Therapeutics [not-audio_url] [/not-audio_url]

Duration: 52:20
We love to hear from our listeners. Send us a message. The latest in our series of Business of Biotech podcasts recorded in-person at JPM in San Francisco features an inspiring conversation with Affinia Therapeutics CEO…
BoB@JPM: Owen Hughes & Brad Sitko, XOMA Royalty [not-audio_url] [/not-audio_url]

Duration: 56:27
We love to hear from our listeners. Send us a message. On this episode of the Business of Biotech, recorded on-site at the 2025 JP Morgan Healthcare Conference, we explore a new approach to biotech financing with XOMA Ro…
BoB@JPM: Tom Chalberg, Ph.D., Genascence [not-audio_url] [/not-audio_url]

Duration: 48:00
We love to hear from our listeners. Send us a message. Recorded in-person at the JP Morgan Healthcare Conference in San Franscisco, this episode finds Matt Pillar and Ben Comer exploring the evolution of gene therapy wit…
BoB@JPM: Ran Zheng, Landmark Bio [not-audio_url] [/not-audio_url]

Duration: 37:00
We love to hear from our listeners. Send us a message. Ran Zhang was hire number one at Landmark Bio back in 2021. Today, she's CEO of the 70+ employee cell and gene therapy manufacturer. We caught up with her and Life S…
BoB@JPM: Peter Anastasiou, Capsida Biotherapeutics [not-audio_url] [/not-audio_url]

Duration: 45:07
We love to hear from our listeners. Send us a message. From the JP Morgan Healthcare Conference in San Francisco, Peter Anastasiou, CEO of Capsida Biotherapeutics, discusses his journey from big pharma to biotech and the…
BoB@JPM: Stefan Scherer, M.D., Ph.D., 3T Bioscience [not-audio_url] [/not-audio_url]

Duration: 43:00
We love to hear from our listeners. Send us a message. From the JP Morgan Healthcare Conference in San Francisco, Dr. Stefan Scherer shares insight from 3T Bioscience's transition from clinical medicine to drug developme…
The Business Of CNS with Acumen's Jim Doherty, Ph.D. [not-audio_url] [/not-audio_url]

Duration: 47:51
We love to hear from our listeners. Send us a message. Life Science Leader's Ben Comer and Acumen Pharmaceuticals' Dr. Jim Doherty join the Business of Biotech to discuss Dr. Doherty's lifelong, singular focus on researc…
High-Throughput Discovery With Bioptic's Andrey Dobry [not-audio_url] [/not-audio_url]

Duration: 1:13:36
We love to hear from our listeners. Send us a message. Andrey Doronichev, known to many simply as Dobry, is perhaps best known for taking YouTube mobile. You heard that right. If it weren't for him and the teams he led,…